DS
EDIT icon

David Shaw’s Editas Medicine EDIT Stock Holding History

David Shaw’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$266K – 5628
2021
Q4 		$266K Hold
10,000
– – ﹤0.01% 4735
2021
Q3 		$411K Sell
10,000
-70,000
-88% -$3.84M ﹤0.01% 4195
2021
Q2 		$4.53M Buy
+80,000
New +$2.95M ﹤0.01% 2143
2019
Q1 		– Sell
-40,000
Closed -$910K – 3671
2018
Q4 		$910K Buy
+40,000
New +$1.09M ﹤0.01% 2726

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

David Shaw's EDIT Position: Q2 2026 in Review

David Shaw reduced its Editas Medicine (EDIT) stake by 2.2% in Q2 2026, selling an estimated $125K and leaving 1,901,002 shares worth $6.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

David Shaw first reported a position in EDIT in Q4 2016 and has held it in 39 quarters since. The position peaked at $98.8M in Q4 2020. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • David Shaw held 1,901,002 shares of Editas Medicine worth $6.16M as of Q2 2026.
  • David Shaw sold 42,891 Editas Medicine shares in Q2 2026, an estimated $125K.
  • Editas Medicine made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2235 holding.
  • David Shaw first reported a position in Editas Medicine in Q4 2016 and has held it in 39 quarters since.
  • David Shaw's Editas Medicine position peaked at $98.8M in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.